The model for end-stage liver disease-based Japan Integrated Scoring system may have a better predictive ability for patients with hepatocellular carcinoma undergoing locoregional therapy

Cancer ◽  
2006 ◽  
Vol 107 (1) ◽  
pp. 141-148 ◽  
Author(s):  
Teh-Ia Huo ◽  
Han-Chieh Lin ◽  
Yi-Hsiang Huang ◽  
Jaw-Ching Wu ◽  
Jen-Huei Chiang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Disease ◽  
Scoring System ◽  
Predictive Ability ◽  
Locoregional Therapy ◽  
End Stage Liver Disease ◽  
End Stage

PNPLA3 in end-stage liver disease: Alcohol consumption, hepatocellular carcinoma development, and transplantation-free survival

2014 ◽  
Vol 29 (7) ◽  
pp. 1477-1484 ◽  
Author(s):  
Kilian Friedrich ◽  
Andreas Wannhoff ◽  
Stefan Kattner ◽  
Maik Brune ◽  
Johannes Roksund Hov ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Disease ◽  
Alcohol Consumption ◽  
Free Survival ◽  
End Stage Liver Disease ◽  
End Stage

scholarly journals Data linkage to monitor hepatitis C‐associated end‐stage liver disease and hepatocellular carcinoma inpatient stays in England

2019 ◽  
Vol 27 (1) ◽  
pp. 20-27
Author(s):  
Georgina Ireland ◽  
Ruth Simmons ◽  
Matthew Hickman ◽  
Ross Harris ◽  
Mary Ramsay ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Disease ◽  
Hepatitis C ◽  
Data Linkage ◽  
End Stage Liver Disease ◽  
End Stage

Regional Variation in Appropriateness of Non-Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception

2020 ◽  
Vol 230 (4) ◽  
pp. 503-512.e8
Author(s):  
Robert M. Cannon ◽  
Eric G. Davis ◽  
David S. Goldberg ◽  
Raymond J. Lynch ◽  
Malay B. Shah ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Disease ◽  
Regional Variation ◽  
End Stage Liver Disease ◽  
End Stage

scholarly journals Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma Patients

Oncology ◽  
2020 ◽  
Vol 98 (12) ◽  
pp. 836-846
Author(s):  
Reham Abdel-Wahab ◽  
Manal M. Hassan ◽  
Bhawana George ◽  
Roberto Carmagnani Pestana ◽  
Lianchun Xiao ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Disease ◽  
Growth Factor ◽  
Meld Score ◽  
Waiting List ◽  
Survival Prediction ◽  
Insulin Like Growth Factor ◽  
Priority Assignment ◽  
End Stage Liver Disease ◽  
End Stage

<b><i>Background:</i></b> Liver reserve affects survival in hepatocellular carcinoma (HCC). Model for End-Stage Liver Disease (MELD) score is used to predict overall survival (OS) and to prioritize HCC patients on the transplantation waiting list, but more accurate models are needed. We hypothesized that integrating insulin-like growth factor 1 (IGF-1) levels into MELD score (MELD-IGF-1) improves OS prediction as compared to MELD. <b><i>Methods:</i></b> We measured plasma IGF-1 levels in training (<i>n</i> = 310) and validation (<i>n</i> = 155) HCC cohorts and created MELD-IGF-1 score. Cox models were used to determine the association of MELD and MELD-IGF-1 with OS. Harrell’s c-index was used to compare the predictive capacity. <b><i>Results:</i></b> IGF-1 was significantly associated with OS in both cohorts. Patients with an IGF-1 level of ≤26 ng/mL in the training cohort and in the validation cohorts had significantly higher hazard ratios than patients with the same MELD but IGF-1 &#x3e;26 ng/mL. In both cohorts, MELD-IGF-1 scores had higher c-indices (0.60 and 0.66) than MELD scores (0.58 and 0.60) (<i>p</i> &#x3c; 0.001 in both cohorts). Overall, 26% of training and 52.9% of validation cohort patients were reclassified into different risk groups by MELD-IGF-1 (<i>p</i> &#x3c; 0.001). <b><i>Conclusions:</i></b> After independent validation, the MELD-IGF-1 could be used to risk-stratify patients in clinical trials and for priority assignment for patients on liver transplantation waiting list.

Sign in / Sign up

Export Citation Format

Share Document